Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE endorses drug-eluting stents

This article was originally published in The Gray Sheet

Executive Summary

UK National Institute for Clinical Excellence issues Oct. 22 1guidance on the use of DES, culminating an 18-month review process. The guidance follows a September final appraisal determination (2"The Gray Sheet" Sept. 22, 2003, In Brief)...

You may also be interested in...

NICE endorses coronary stents

J&J Cypher and Boston Scientific Taxus drug-eluting stents are recommended for coronary artery disease where percutaneous intervention is clinically appropriate for symptomatic angina/acute myocardial infarction with target arteries less than 3 mm in diameter or lesions longer than 15 mm, UK's National Institute for Clinical Excellence states in a recent final appraisal determination. NICE issued its preliminary recommendations for coronary stents in June (1"The Gray Sheet" June 30, 2003, p. 10)...

COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers

First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.

Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts